NASDAQ:EVFM Evofem Biosciences (EVFM) Stock Price, News & Analysis $0.0075 0.00 (-6.25%) As of 01:30 PM Eastern Add Compare Share Share Stock Analysis Stock AnalysisChartCompetitorsHeadlinesSEC FilingsTrendsBuy This Stock About Evofem Biosciences Stock (NASDAQ:EVFM) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Evofem Biosciences alerts:Sign Up Key Stats Today's Range$0.0071▼$0.008050-Day Range$0.0070▼$0.009752-Week Range$0.00▼$0.02Volume132,618 shsAverage Volume217,306 shsMarket Capitalization$993.98 thousandP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview Evofem Biosciences is a clinical‐stage biotechnology company based in San Diego, California, specializing in women’s sexual and reproductive health. Founded in 2013 as a spin-out of the Scripps Research Institute, the company is focused on developing non-hormonal, on-demand products that address unmet needs in contraception and the prevention of sexually transmitted infections. The company’s lead commercial product, Phexxi, is an FDA-approved, non-hormonal vaginal gel that maintains the vagina’s natural pH to reduce the risk of unintended pregnancy. Phexxi offers an alternative to hormonal birth control by using a proprietary combination of lactic acid, citric acid and potassium bitartrate. Beyond its marketed offering, Evofem maintains a research and development pipeline that includes additional vaginally administered candidates aimed at preventing chlamydia and gonorrhea, reflecting its commitment to broadening women’s health options. Evofem Biosciences conducts its primary operations in the United States and engages with healthcare providers, payers and distribution partners to support product adoption and access. The company is led by a management team with experience in biotechnology commercialization and women’s health, and it continually explores strategic collaborations to advance its novel therapeutic platform and expand its geographic reach.AI Generated. May Contain Errors. Read More Receive EVFM Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Evofem Biosciences and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. EVFM Stock News HeadlinesEvofem Biosciences Celebrates Shipment of Its 500,000th Unit of PHEXX®, Representing Hormone-Free Protection from Unintended Pregnancy for 6 Million Acts of SexJuly 23, 2026 | finance.yahoo.comEvofem Biosciences Updates Investors via New PresentationJuly 20, 2026 | tipranks.comA letter from Shannon StansberryPorter Stansberry nearly canceled the entire project. When he first saw the claimed returns - only one down year in nearly two decades and total gains of almost 2,000% - his immediate reaction was disbelief. It took a trusted friend's personal vouching for Emmet Savage and a face-to-face trip to Ireland to change his mind. The full documentary, Investigating Project Prophet, is now live.August 19 at 1:00 AM | Porter & Company (Ad)Evofem Biosciences Inc. (EVFM)July 12, 2026 | nasdaq.comHUB Cyber Security Expands Into Women’s Health With Zero-Cash Acquisition of Evofem Notes, Advances Balance Sheet TurnaroundJuly 1, 2026 | finance.yahoo.comEvofem Biosciences Inc. (EVFM) SEC FilingsJune 23, 2026 | nasdaq.comEvofem Reports First Quarter 2026 Financial Results and Provides Business UpdateMay 18, 2026 | businesswire.comEvofem Biosciences Secures Solosec Distribution Deal in AfricaApril 30, 2026 | tipranks.comSee More Headlines EVFM Stock Analysis - Frequently Asked Questions How have EVFM shares performed this year? Evofem Biosciences' stock was trading at $0.0092 on January 1st, 2026. Since then, EVFM shares have decreased by 14.1% and is now trading at $0.0079. How were Evofem Biosciences' earnings last quarter? Evofem Biosciences, Inc. (NASDAQ:EVFM) announced its quarterly earnings data on Friday, June, 16th. The biotechnology company reported ($1.85) earnings per share for the quarter, beating analysts' consensus estimates of ($15.00) by $13.15. The biotechnology company earned $5.81 million during the quarter. Evofem Biosciences had a negative trailing twelve-month return on equity of 91.97% and a negative net margin of 46.42%. When did Evofem Biosciences' stock split? Shares of Evofem Biosciences reverse split on the morning of Thursday, May 18th 2023.The 1-125 reverse split was announced on Thursday, May 18th 2023. The number of shares owned by shareholders was adjusted after the closing bell on Thursday, May 18th 2023. An investor that had 100 shares of stock prior to the reverse split would have 1 shares after the split. How do I buy shares of Evofem Biosciences? Shares of EVFM stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Evofem Biosciences own? Based on aggregate information from My MarketBeat watchlists, some other companies that Evofem Biosciences investors own include Tesla (TSLA), NIO (NIO), Plug Power (PLUG), Meta Platforms (META), Sorrento Therapeutics (SRNE), NVIDIA (NVDA) and Ford Motor (F). Company Calendar Last Earnings6/16/2023Today8/19/2026Fiscal Year End12/31/2026Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Pharmaceuticals Sub-IndustryPharmaceuticals Current SymbolNASDAQ:EVFM CIK1618835 Webwww.evofem.com Phone(858) 550-1900Fax844-828-2010Employees120Year Founded2007Profitability EPS (Trailing Twelve Months)($0.13) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$52.98 million Net Margins-46.42% Pretax Margin-46.42% Return on Equity-91.97% Return on Assets-61.93% Debt Debt-to-Equity RatioN/A Current Ratio0.11 Quick Ratio0.09 Sales & Book Value Annual Sales$11.39 million Price / Sales0.09 Cash FlowN/A Price / Cash FlowN/A Book Value($2.64) per share Price / Book0.00Miscellaneous Outstanding Shares132,530,000Free Float113,118,000Market Cap$1.05 million OptionableNot Optionable Beta-1.32 Social Links The Infrastructure's Backbone: 10 Stocks Powering the AI BuildoutThe AI boom extends far beyond the biggest tech names. Discover 10 companies supplying the memory, storage, networking, semiconductor manufacturing, and power infrastructure that make AI possible. Learn where the next wave of AI investment opportunities may emerge—and the key risks investors should watch as the global AI buildout accelerates.Get This Free Report This page (NASDAQ:EVFM) was last updated on 8/19/2026 by MarketBeat.com Staff. From Our PartnersALERT: Drop these 5 stocks before the market opens tomorrow!The Wall Street Journal is already raising the alarm about a potential market crash, and Weiss Ratings researc...Weiss Ratings | SponsoredLouis Navellier: My #1 AI stock for 2026 (name & ticker inside)Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top...InvestorPlace | SponsoredReady to give options a try? Your first trade (Ticker included) -INSIDETired of trying tactic after tactic when it comes to options trades... only to be met with market noise and st...Base Camp Trading | SponsoredSmall Colorado Company (Backed by Sam Altman) Could Save U.S. Power GridA small Colorado company has secured rights to technology that could prevent the U.S. public power grid from c...Altimetry | SponsoredIran War Shock: What I Was Told In That Private MeetingYou’re Being LIED To About The Iran War Forget EVERYTHING you’ve heard about the Iran war. Especially th...Banyan Hill Publishing | SponsoredMy top 3 AI picks for the next decadeAlexander Green bought Apple in 1996, recommended Nvidia at a split-adjusted 66 cents in 2004, and picked up A...The Oxford Club | SponsoredBuy this stock todayMarc Chaikin, founder of Chaikin Analytics, is sharing a strategy he calls 'Sell This, Buy That' - a way to mo...Chaikin Analytics | SponsoredHere’s the stock symbol I’ve promisedWhitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - b...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Evofem Biosciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Evofem Biosciences With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free EVFM Stock Alerts